Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Veritas In Silico Inc. ( (JP:130A) ).
Veritas In Silico Inc. and The Jikei University School of Medicine have announced the publication of a patent for new nucleic acid drug substances targeting amyotrophic lateral sclerosis (ALS), arising from their joint research on the RNA/DNA-binding protein TDP-43. Building on Professor Hirotaka James Okano’s discovery that inhibitory truncated TDP-43 isoforms may drive ALS by impairing full-length TDP-43 function, Veritas In Silico used its AI-based ibVIS platform to design and optimize nucleic acid candidates that suppress these harmful isoforms, leading to patent filings and the publication of one application. The collaboration exemplifies a proposed “third pathway” for academia-originated drug discovery—early, integrated partnerships between universities and industry to accelerate the translation of mechanistic research into therapeutic candidates, potentially strengthening Veritas In Silico’s positioning in ALS drug innovation and offering a model for addressing other unmet medical needs.
More about Veritas In Silico Inc.
Veritas In Silico Inc., listed on the TSE Growth market, operates in the biopharmaceutical and drug discovery sector, specializing in AI-driven nucleic acid drug design through its ibVIS platform. The company focuses on supporting the development of novel therapeutics that address unmet medical needs by collaborating closely with academic institutions to translate basic disease mechanism research into optimized drug candidates.
Average Trading Volume: 111,484
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.1B
For an in-depth examination of 130A stock, go to TipRanks’ Overview page.